Human CD80/IL2 lentivirus-transduced acute myeloid leukaemia (AML) cells promote natural killer (NK) cell activation and cytolytic activity: implications for a phase I clinical study.
about
The innovative evolution of cancer gene and cellular therapies.DNA-mediated adjuvant immunotherapy extends survival in two different mouse models of myeloid malignanciesClinical evaluation of cellular immunotherapy in acute myeloid leukaemia.Current strategies in immunotherapy for acute myeloid leukemia.Dendritic cells in myelodysplastic syndromes: from pathogenesis to immunotherapy.Cancer Immunotherapy: Whence and Whither.A distinct subset of human NK cells expressing HLA-DR expand in response to IL-2 and can aid immune responses to BCG.
P2860
Q34325544-0BB81709-3BB3-4714-9A65-790F799DA1CDQ36544893-53A4893B-2620-4F4E-B420-85650E8935F6Q37868974-009806D0-4ADE-4804-B24C-C28E7390EC0BQ38068967-3FD18A33-AFB3-446E-A88F-B05C107D5A64Q38110935-BC550D4B-2AA8-45EE-A815-9BDAF17FFEC2Q38737924-A83D4278-6536-4429-9FD4-41A9AD00A421Q42019704-0F179945-BA8B-43B6-A003-54277E646128
P2860
Human CD80/IL2 lentivirus-transduced acute myeloid leukaemia (AML) cells promote natural killer (NK) cell activation and cytolytic activity: implications for a phase I clinical study.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh-hant
name
Human CD80/IL2 lentivirus-tran ...... for a phase I clinical study.
@en
Human CD80/IL2 lentivirus-transduced acute myeloid leukaemia
@nl
type
label
Human CD80/IL2 lentivirus-tran ...... for a phase I clinical study.
@en
Human CD80/IL2 lentivirus-transduced acute myeloid leukaemia
@nl
prefLabel
Human CD80/IL2 lentivirus-tran ...... for a phase I clinical study.
@en
Human CD80/IL2 lentivirus-transduced acute myeloid leukaemia
@nl
P2093
P50
P1476
Human CD80/IL2 lentivirus-tran ...... for a phase I clinical study.
@en
P2093
David Darling
Ghulam J Mufti
Linda Barber
Lucas Chan
Nicola Hardwick
Wendy Ingram
P304
P356
10.1111/J.1365-2141.2009.07684.X
P407
P577
2009-04-20T00:00:00Z